A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer

Anthony Rhodes, Bharat Jasani, Jérôme Couturier, Mark J. McKinley, John M. Morgan, Andrew R. Dodson, Hossein Navabi, Keith D. Miller, André J. Balaton

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

To ensure the accuracy and reproducibility of immunohistochemical assays for determining HER-2/neu status of patients with breast cancer, a reliable standard for monitoring assay sensitivity is necessary. We optimally fixed and paraffin processed human ovarian and breast carcinoma cell lines SKOV-3, MDA-MB-453, BT-20, and MCF-7 in quantities sufficient to meet the needs of a laboratory for the foreseeable future. The material was tested, alongside Hercep Test kit cell lines (DAKO, Carpinteria, CA), by 7 breast cancer centers in the United Kingdom and France with different immunohistochemical assays and markers. The cell lines also were analyzed by fluorescence in situ hybridization (FISH) by 2 centers using HER-2/neu kits. FISH produced 100% agreement between the 2 centers: SKOV-3 and MDA-MB-453 showed HER-2/neu amplification and BT-20 and MCF-7 did not. Immunohistochemical analysis and a common evaluation method produced 100% agreement that SKOV-3 and MCF-7 showed 3+ and zero HER-2/neu overexpression, respectively. For MDA-MB-453, there was 71% (5/7) concordance of 2+ immunohistochemical staining and 86% (6/7) concordance of zero or 1+ staining for BT-20. The cell lines provide a valuable standard for gauging HER-2/neu assay sensitivity irrespective of the antibody, antigen retrieval system, detection system, or method of evaluation used.

Original languageEnglish
Pages (from-to)81-89
Number of pages9
JournalAmerican Journal of Clinical Pathology
Volume117
Issue number1
DOIs
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

Quality Control
Paraffin
Formaldehyde
Breast Neoplasms
Cell Line
Fluorescence In Situ Hybridization
Staining and Labeling
France
Antigens
Antibodies
MB 3

Keywords

  • Cell line standard
  • Fluorescence in situ hybridization
  • HER-2/neu
  • Immunohistochemistry
  • Quality control

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer. / Rhodes, Anthony; Jasani, Bharat; Couturier, Jérôme; McKinley, Mark J.; Morgan, John M.; Dodson, Andrew R.; Navabi, Hossein; Miller, Keith D.; Balaton, André J.

In: American Journal of Clinical Pathology, Vol. 117, No. 1, 2002, p. 81-89.

Research output: Contribution to journalArticle

Rhodes, Anthony ; Jasani, Bharat ; Couturier, Jérôme ; McKinley, Mark J. ; Morgan, John M. ; Dodson, Andrew R. ; Navabi, Hossein ; Miller, Keith D. ; Balaton, André J. / A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer. In: American Journal of Clinical Pathology. 2002 ; Vol. 117, No. 1. pp. 81-89.
@article{7aea021c94ec4778bed125e25f7fcbe3,
title = "A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer",
abstract = "To ensure the accuracy and reproducibility of immunohistochemical assays for determining HER-2/neu status of patients with breast cancer, a reliable standard for monitoring assay sensitivity is necessary. We optimally fixed and paraffin processed human ovarian and breast carcinoma cell lines SKOV-3, MDA-MB-453, BT-20, and MCF-7 in quantities sufficient to meet the needs of a laboratory for the foreseeable future. The material was tested, alongside Hercep Test kit cell lines (DAKO, Carpinteria, CA), by 7 breast cancer centers in the United Kingdom and France with different immunohistochemical assays and markers. The cell lines also were analyzed by fluorescence in situ hybridization (FISH) by 2 centers using HER-2/neu kits. FISH produced 100{\%} agreement between the 2 centers: SKOV-3 and MDA-MB-453 showed HER-2/neu amplification and BT-20 and MCF-7 did not. Immunohistochemical analysis and a common evaluation method produced 100{\%} agreement that SKOV-3 and MCF-7 showed 3+ and zero HER-2/neu overexpression, respectively. For MDA-MB-453, there was 71{\%} (5/7) concordance of 2+ immunohistochemical staining and 86{\%} (6/7) concordance of zero or 1+ staining for BT-20. The cell lines provide a valuable standard for gauging HER-2/neu assay sensitivity irrespective of the antibody, antigen retrieval system, detection system, or method of evaluation used.",
keywords = "Cell line standard, Fluorescence in situ hybridization, HER-2/neu, Immunohistochemistry, Quality control",
author = "Anthony Rhodes and Bharat Jasani and J{\'e}r{\^o}me Couturier and McKinley, {Mark J.} and Morgan, {John M.} and Dodson, {Andrew R.} and Hossein Navabi and Miller, {Keith D.} and Balaton, {Andr{\'e} J.}",
year = "2002",
doi = "10.1309/4NCM-QJ9W-QM0J-6QJE",
language = "English",
volume = "117",
pages = "81--89",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "1",

}

TY - JOUR

T1 - A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer

AU - Rhodes, Anthony

AU - Jasani, Bharat

AU - Couturier, Jérôme

AU - McKinley, Mark J.

AU - Morgan, John M.

AU - Dodson, Andrew R.

AU - Navabi, Hossein

AU - Miller, Keith D.

AU - Balaton, André J.

PY - 2002

Y1 - 2002

N2 - To ensure the accuracy and reproducibility of immunohistochemical assays for determining HER-2/neu status of patients with breast cancer, a reliable standard for monitoring assay sensitivity is necessary. We optimally fixed and paraffin processed human ovarian and breast carcinoma cell lines SKOV-3, MDA-MB-453, BT-20, and MCF-7 in quantities sufficient to meet the needs of a laboratory for the foreseeable future. The material was tested, alongside Hercep Test kit cell lines (DAKO, Carpinteria, CA), by 7 breast cancer centers in the United Kingdom and France with different immunohistochemical assays and markers. The cell lines also were analyzed by fluorescence in situ hybridization (FISH) by 2 centers using HER-2/neu kits. FISH produced 100% agreement between the 2 centers: SKOV-3 and MDA-MB-453 showed HER-2/neu amplification and BT-20 and MCF-7 did not. Immunohistochemical analysis and a common evaluation method produced 100% agreement that SKOV-3 and MCF-7 showed 3+ and zero HER-2/neu overexpression, respectively. For MDA-MB-453, there was 71% (5/7) concordance of 2+ immunohistochemical staining and 86% (6/7) concordance of zero or 1+ staining for BT-20. The cell lines provide a valuable standard for gauging HER-2/neu assay sensitivity irrespective of the antibody, antigen retrieval system, detection system, or method of evaluation used.

AB - To ensure the accuracy and reproducibility of immunohistochemical assays for determining HER-2/neu status of patients with breast cancer, a reliable standard for monitoring assay sensitivity is necessary. We optimally fixed and paraffin processed human ovarian and breast carcinoma cell lines SKOV-3, MDA-MB-453, BT-20, and MCF-7 in quantities sufficient to meet the needs of a laboratory for the foreseeable future. The material was tested, alongside Hercep Test kit cell lines (DAKO, Carpinteria, CA), by 7 breast cancer centers in the United Kingdom and France with different immunohistochemical assays and markers. The cell lines also were analyzed by fluorescence in situ hybridization (FISH) by 2 centers using HER-2/neu kits. FISH produced 100% agreement between the 2 centers: SKOV-3 and MDA-MB-453 showed HER-2/neu amplification and BT-20 and MCF-7 did not. Immunohistochemical analysis and a common evaluation method produced 100% agreement that SKOV-3 and MCF-7 showed 3+ and zero HER-2/neu overexpression, respectively. For MDA-MB-453, there was 71% (5/7) concordance of 2+ immunohistochemical staining and 86% (6/7) concordance of zero or 1+ staining for BT-20. The cell lines provide a valuable standard for gauging HER-2/neu assay sensitivity irrespective of the antibody, antigen retrieval system, detection system, or method of evaluation used.

KW - Cell line standard

KW - Fluorescence in situ hybridization

KW - HER-2/neu

KW - Immunohistochemistry

KW - Quality control

UR - http://www.scopus.com/inward/record.url?scp=0036141363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036141363&partnerID=8YFLogxK

U2 - 10.1309/4NCM-QJ9W-QM0J-6QJE

DO - 10.1309/4NCM-QJ9W-QM0J-6QJE

M3 - Article

VL - 117

SP - 81

EP - 89

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 1

ER -